lorlatinib will reduce the extent or impact of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Prevent use of lorlatinib with CYP3A substrates, wherever minimal focus alterations could lead to really serious therapeutic failures on the substrate.